Auxly Cannabis to acquire CRO KGK for $12.3M in cash, stock deal

Close-up of handshake between person in suit and person in business shirt.
Auxly Cannabis Group to buy KGK, a Canadian CRO focused on health and wellness, in a cash and stock deal worth $12.3 million. (Getty Images)

Auxly Cannabis Group reached an agreement to acquire KGK, a Canadian CRO focused on health and wellness, in a cash and stock deal worth $12.3 million.

Auxly, which is based in Vancouver, said the deal will advance its plans for product development with its subsidiary, Dosecann.

As part of the deal, Auxly will pick up all issued and outstanding shares of KGK, which will become a wholly owned subsidiary when the sale is completed. The deal is subject to regulatory approvals.

Training Course

BioBasics: Biotech For The Non-Scientist

BioBasics: Biotech for the Non-Scientist is a two-day course for those who want to better understand the science driving the industry. The course starts with basic scientific concepts and quickly delves into the causes of genetic and infectious disease and the therapeutic strategies used to mitigate disease. The latest innovations in immunotherapies, gene therapy, checkpoint inhibitors, CAR-T and more are explained.

In recent years, KGK began branching out from the health and wellness space to include cannabinoid and animal products.

“We believe KGK’s track record of success as a leading health and wellness focused contract research organization in North America is a testament to their ability to add a significant amount of value to Auxly’s midstream business segment,” Hugo Alves, Auxly’s president, said in a statement.

KGK shareholders will receive 4,132,231 Auxly shares priced at $1.21 per common share, the company said. The remainder of the purchase price will be paid in cash.

Suggested Articles

Gottlieb challenged industry and academia to invest in new approaches and realign incentives to make clinical research more agile and effective.

Chinese biotech HitGen has inked a collaboration deal with India’s Sun Pharma Advanced Research arm to identify novel small molecule leads.

Charles River Labs has inked a licensing deal with drug discovery and development services provider Crown Bioscience for expanded access to the ZDSD rat model.